Bulk Pharmaceutical API Sources for metronidazole

Bulk Pharmaceutical API Sources for metronidazole

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		M1547_SIGMA
Vitas-M Laboratory		STK177359
TCI (Tokyo Chemical Industry)		M0924

Bulk API Sources for Metronidazole

Last updated: February 20, 2026

Metronidazole is an antibacterial and antiprotozoal agent used primarily for intra-abdominal infections, gynecological infections, and protozoal infections. The global supply chain comprises numerous manufacturers, with key players based in India, China, and Europe. This overview details significant sources, manufacturing capacities, and market dynamics.

Major Regions and Manufacturers

India

India dominates the production of Metronidazole API, with over 60% of global supply. The industry includes established players like:

• Cadila Pharmaceuticals
• IPCA Labs
• Aurobindo Pharma
• Hetero Labs
• Mylan (now part of Viatris)

These companies operate large-scale plants capable of producing thousands of metric tons annually, adhering to ISO standards and Good Manufacturing Practices (GMP).

China

Chinese manufacturers supply approximately 20-25% of global API demand. Companies such as:

• Zhejiang Huahong Pharmaceutical
• Heilongjiang Beidahuang Pharma
• Zhejiang Tianyu Pharmaceutical

produce APIs in compliance with Chinese GMP standards, with increasing export volumes due to competitive pricing.

Europe

European API manufacturers account for roughly 10-15% of the market, with firms like:

• Evonik Industries
• Sandoz (Novartis)
• Sanofi

These companies primarily supply to regulated markets, with manufacturing often located in Germany, France, and Switzerland.

Production Capacities and Market Share

Region	Estimated Market Share	Typical Annual Capacity (tons)	Key Companies
India	60%	10,000 – 15,000	Aurobindo, Hetero, IPCA
China	20-25%	4,000 – 7,000	Zhejiang Huahong, Heilongjiang Beidahuang
Europe	10-15%	2,000 – 3,000	Evonik, Sanofi, Sandoz

Manufacturers report capacities ranging from 500 to over 3,000 tons annually per facility, often expanding through capacity upgrades.

Supply Chain Dynamics and Regulatory Factors

• Regulatory Conformity: API manufacturers must comply with regional regulations, including US FDA, EMA, and South Asian GMP standards.
• Localization: Indian and Chinese producers have localized supply chains, reducing costs and delivery times.
• Quality Assurance: Vendors providing APIs for regulated markets document rigorous quality control, including batch records and stability testing.

Key API Suppliers and Their Certifications

Manufacturer	Certifications	Production Capacity (tons)	Market Focus
Aurobindo Pharma	US FDA, EU GMP	3,000	Global, regulated markets
Zhejiang Huahong	Chinese GMP, ISO	2,500	Asia, emerging markets
Sanofi (via Outsourcing)	EU GMP, WHO Prequalified	1,200	Europe, North America
IPCA Labs	Indian GMP, US FDA	2,000	Indian subcontinent, exports

Market Trends and Outlook

• Continued capacity expansion is driven by increasing demand for generic formulations.
• Chinese and Indian manufacturers are investing in compliances and quality certifications to access regulated markets.
• Price competition among low-cost producers maintains downward pressure on API prices.
• Regulatory scrutiny, especially from US and European authorities, tightens quality standards.

Sources of Reliable API Procurement

• Contract manufacturers (CMOs) with proven quality systems.
• Direct supplier engagement for bulk procurement.
• Certification verification via agencies like US FDA, EMA, and WHO.

Closing Summary

The primary sources for bulk Metronidazole API are predominantly Indian and Chinese manufacturers, with European firms serving high-quality demand markets. Capacity expansions and regulatory compliance shape supply continuity and quality standards. Suppliers with ISO, GMP, and FDA certifications dominate the regulated segments.

---

Key Takeaways

• Indian firms produce over 60% of global Metronidazole API, with capacity exceeding 10,000 tons annually.
• Chinese suppliers fulfill approximately one-fifth of demand, focusing on cost competitiveness.
• European companies supply a smaller portion, mainly for high-regulatory market needs.
• Capacity is expanding in India and China, driven by rising global demand.
• Rigorous regulatory compliance remains essential for API sourcing for branded and generic products.

---

FAQs

1. Which countries dominate the production of Metronidazole API?
India leads with over 60% market share, followed by China with approximately 20-25%, and Europe with 10-15%.

2. Are Chinese API manufacturers compliant with international standards?
Many Chinese producers adhere to Chinese GMP, with some achieving WHO, EMA, and FDA certifications to serve regulated markets.

3. What are typical annual production capacities for Metronidazole API?
Capacities range from 500 tons to over 3,000 tons per manufacturer annually, depending on the facility and region.

4. How does regulatory compliance affect supplier selection?
Suppliers holding stringent certifications (US FDA, EMA, ISO, WHO) are preferred for regulated market procurement, ensuring quality and market access.

5. Is supply security impacted by capacity constraints?
Yes. Capacity expansions and new entrants mitigate risks, but supply chain disruptions or regulatory delays can affect availability.

---

References

[1] U.S. Food and Drug Administration. (2022). API manufacturing standards and certifications.
[2] European Medicines Agency. (2023). Standards for Active Pharmaceutical Ingredients.
[3] Indian Drug Quality Control. (2022). API production capacities and market share analysis.
[4] Chinese Pharmaceutical Industry Association. (2023). API manufacturing overview and compliance updates.
[5] MarketWatch. (2023). Global API market trends and capacity forecasts.